Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe
- Conditions
- Multiple Myeloma
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 705
- Registration Number
- NCT03091127
- Locations
- 🇦🇹
Kardinal Schwarzenbergsches Krankenhaus, Schwarzach im Pongau, Austria
🇧🇪Centres Hospitaliers Jolimont - Hopital de Jolimont, Haine Saint Paul - La Louviere, Belgium
🇦🇹Universitaetsklinikum Allgemeines Krankenhaus Wien, Wien, Austria
Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma
- Conditions
- Unresectable Stage IIIB-IV Malignant Melanoma
- Interventions
- First Posted Date
- 2017-02-27
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 18
- Registration Number
- NCT03064763
- Locations
- 🇯🇵
Niigata Cancer Center Hospital, Niigata-shi, Niigata, Japan
🇯🇵Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan
🇯🇵National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
- Conditions
- Relapsed and Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 126
- Registration Number
- NCT03029234
- Locations
- 🇨🇳
Guangzhou First Peoples Hospital, Guangzhou, Guangdong, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳West China Hospital, Sichuang University, Chengdu, Sichuan, China
Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma
- Conditions
- High-risk Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 47
- Registration Number
- NCT03023878
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
- Conditions
- ANCA-Associated Vasculitis
- Interventions
- First Posted Date
- 2016-12-16
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 331
- Registration Number
- NCT02994927
- Locations
- 🇬🇧
Clinical Trial Site, Westcliff-on-Sea, United Kingdom
Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States
- Conditions
- DyslipidemiaMedical Conditions to be StudiedASCVD Management
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 5006
- Registration Number
- NCT02993120
- Locations
- 🇺🇸
Research Site, Bellevue, Washington, United States
Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis
- Conditions
- Arthritis, Rheumatoid; Arthritis, Psoriatic
- Interventions
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 111
- Registration Number
- NCT02986139
- Locations
- 🇵🇷
Research Site, Ponce, Puerto Rico
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 35
- Registration Number
- NCT02961881
- Locations
- 🇦🇺
St Vincents Hospital Melbourne, Fitzroy, Victoria, Australia
🇩🇪Universitaetsklinikum Carl Gustav Carus, Dresden, Germany
🇮🇹IRCCS Ospedale San Raffaele, Milano, Italy
Evolocumab Pregnancy Exposure Registry
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 140
- Registration Number
- NCT02957604
APremilast After FumaRic Acid Ester Treatment
- Conditions
- Psoriasis
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 687
- Registration Number
- NCT02954081
- Locations
- 🇩🇪
Site, Hamburg, Germany